Human ether-à-go-go related gene (hERG) 1 channels conduct the rapid delayed rectifier K + current (I Kr ) and are essential for the repolarization of the cardiac action potential. hERG1 inhibition by structurally diverse drugs may lead to life threatening arrhythmia. Putative binding determinants of hERG1 channel blockers include T623, S624 and V625 on the pore helix, and residues G648, Y652 and F656, located on segment S6. We and others have previously hypothesized that additional binding determinants may be located on helix S5, which is in close contact with the S6 segments. In order to test this hypothesis, we performed a detailed investigation combining ionic current measurements with two-microelectrode voltage clamp and molecular modeling techniques. We identified a novel aromatic high affinity binding determinant for blockers located in helix S5, F557, which is equally potent as Y652. Modeling supports a direct interaction with the outer pore helix.Human ether-à-go-go related gene (hERG) 1 channels conduct the rapid delayed rectifier K + current (I Kr ) and are essential for regulating the duration of the plateau phase of the cardiac action potential 1,2 . Inherited loss-of-function mutations in hERG1 can lead to life threatening torsades de pointes (TdP) arrhythmia 3 , while gain-of-function mutations are associated with short QT syndrome 4 . Most frequently, TdP arrhythmia is an acquired disorder, resulting from "off-target" block of this channel by structurally diverse drugs including antiarrhythmics, antihistamines, antipsychotics and antibiotics 5 . Since this inhibition can lead to sudden cardiac death, several pharmaceuticals such as cisapride or terfenadine were withdrawn from the market, or had their use severely restricted 6,7 . Recently, the Cardiac Safety Research Consortium (CSRC) and the Food and Drug Administration (FDA) proposed a new cardiac safety paradigm labelled "Comprehensive In Vitro Proarrhythmia Assay" (CiPA). The new CiPA guidelines emphasize the importance of studying pharmacological effects of drugs on three different ion channel types including hERG, Nav1.5 and Cav1.2, which proposed to play an important role in shaping the ventricular action potential 8 . hERG1 blockers might also have beneficial therapeutic potential. During routine preclinical screening for hERG1, new modulators, so-called activators, have been identified. These modulators may have the potential of shortening the action potential duration 9 . Thus, they might be beneficial for the treatment of inherited long QT syndrome.Great efforts have been directed toward a better understanding of the molecular and structural mechanisms of hERG1 channel drug interactions, including in vivo, in vitro and in silico approaches (for a recent reviews see Durdagi, S. et al. 10 and Vandenberg, J. et al. 11 ). Substantial progress has been made by identifying amino acids essential for drug block. The majority of hERG inhibitors are interacting with the pore module. This homo tetrameric module consists of an outer S5 helix, a...